Pancreatic cancer bone metastasis
Also it is difficult to make the differential diagnosis with the pseudotumoral chronic pancreatitis, which has similar imagistic and clinical features, so pancreatic cancer bone metastasis with hystopathologic diagnosis is needed. The preoperative staging of the pancreatic cancer has a limited accuracy max. Up to now, no predictive tumor or host features e.
In practice, the hepatic metastases under 1 cm are often unidentified before surgery through conventional imagistic methods, being detected only during surgery or becoming visible during the immediate postsurgical follow-up. New accurate and cost-efficient diagnosis tools are necessary, with role of predictive biomarker for malignancy in doubtful cases or in patients with risk factors diabetes, chronic pancreatitis and useful as a prognostic indicator in cases already diagnosed.
Such markers have to be looked for among the tumoral molecular factors involved in tumorigenesis process.
The modifications of the human genome, reflected by mutations of proto-oncogenes or tumoral suppression genes have been long researched on the surgical samples or on cell cultures. Also, through studies of proteomics, proteins over expressed in the malignant pancreatic tissue were selected over the benign ones.
Unfortunately, important genetic information regarding the locally advanced or metastatic tumors was lost, pancreatic cancer bone metastasis considered unfitted for surgery. Therefore, the use of tissular material obtained from these unoperated tumors could emphasize, according to the advanced stage of the disease, the genome and proteic expression modifications, by establishing a genetic algorithm, pancreatic cancer bone metastasis for metastasis and with prognostic implications.
Although the pancreas has a deep location in the abdomen and pancreatic biopsies done by transabdominal procedures are associated with serious risk of fistulas, the pancreatic tissular samples for this proposal pancreatic cancer bone metastasis be obtained through a minimum invasive method, pancreatic cancer bone metastasis ultrasonography using fine needle aspiration.
The materia resulted, evaluated through the microarray technique and proteomic analysis, will pancreatic cancer bone metastasis a quick analysis of the set of molecular modifications from the pancreatic cancer, comparative with a group of chronic pancreatitis.
The tumoral genetic modifications, expressed through the proteic synthesis in the pancreatic cancer bone metastasis tissue, can be found in serum, where from, once identified, they can be considered signals of morbid status of the body.
Although plasma or serum is easy to be sampled, the proteic biomarkers are difficult to be identified because their concentration is less than those of dominant proteins with high molecular weight albumin, globulins. The method proposed for protein assessment in this project, mass spectrometry, allow the identification of the proteins with low molecular mass, hyper expressed in hpv cervical cancer procedure serum of patients with pancreatic tumors comparatively with a control group.
Pancreatic cancer bone metastasis disappearance or decrease of their concentration after surgical removal of the tumor will represent starting points for the identification of certain biomarkers in early pancreatic cancer.
